Researchers from Vrise Therapeutics Inc. and Vegen Therapeutics Pvt Ltd. presented preclinical data for VRTX-531, an allosteric inhibitor of ubiquitin carboxyl-terminal hydrolase 1 (USP1), being ...

during a poster session at the 36th EORTC-NCI-AACR Symposium (ENA 2024). The data demonstrate that in preclinical models, treatment with SGR-3515 results in synergistic anti-tumor activity that ...

or “fadra”, as a single agent was presented as a poster at the 2024 EORTC-NCI-AACR 36 th Symposium on Molecular Targets and Cancer Therapeutics (“Triple Meeting”), in Barcelona ...

The inhibition of hematopoietic progenitor kinase 1 (HPK1), predominantly expressed in immune cells, has proven effective in reducing tumor growth across cancer immune response modulation.

ASTX528 is a novel small molecule CBP/p300 HAT domain inhibitor with potent in vivo activity and a favourable safety profile in preclinical species that was discovered by Astex using its proprietary ...

“We look forward to achieving our goal of being a catalyst for the next big discovery.” ...

1Arizona Cancer Evolution Center, The Biodesign Institute, Arizona State University, Tempe, Arizona. 2University of Arizona Cancer Center, Tucson, Arizona. 3University of Arizona College of Medicine, ...